GOLY yields 9.09% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 2
Combined, GOLY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GOLY + ABBV for your $10,000?
GOLY aims to provide monthly distributions through a diversified portfolio of bonds, gold, and commodities. However, these payments may include a return of capital rather than net profits. Investments consist of USD-denominated corporate bonds and US Treasuries, maintaining investment-grade credit quality through quantitative metrics and fundamental analysis. Simultaneously, it hedges against inflation and currency risks via total return swaps on near-month gold futures. Lastly, it uses a long/short approach to energy, industrial metals, and precious metals commodities, capitalizing on market inefficiencies. Using leverage, the fund achieves 200% notional exposure, with 100% to bonds and 100% to gold and commodities. A portion of the strategy is executed through a Cayman Islands subsidiary, which manages swaps and collateral. Note that using leverage magnifies potential gains and losses, particularly in volatile markets. Before Feb 1, 2024, the fund traded under the ticker GLDB.
Full GOLY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.